Compare TTRX & NNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTRX | NNY |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2M | 164.1M |
| IPO Year | N/A | N/A |
| Metric | TTRX | NNY |
|---|---|---|
| Price | $8.03 | $8.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 125.6K | 27.2K |
| Earning Date | 05-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $7.94 |
| 52 Week High | $11.69 | $8.94 |
| Indicator | TTRX | NNY |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 28.25 |
| Support Level | $4.40 | $8.16 |
| Resistance Level | $10.48 | $8.61 |
| Average True Range (ATR) | 0.89 | 0.13 |
| MACD | -0.29 | -0.05 |
| Stochastic Oscillator | 3.98 | 15.14 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.